1. Главная
  2. Ресурсы
  3. Библиотечный поиск
EULAR recommendationsfor the management ofrheumatoid arthritiswith synthetic andbiologicaldisease-modifyingantirheumatic drugs:2016 update Josef S SmolenRobert LandewéJohannes Bijlsma2017 год

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
review

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to—or adding—another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR9s most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
Год издания: 2017
Авторы: Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, J. Nam, Sofía Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Christopher D. Buckley, Frank Buttgereit, Vivian P. Bykerk, Myrna Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan J. Gómez‐Reino, Laure Gossec, J.-E. Gottenberg, Johanna M W Hazes, T. Huizinga, Meghna Jani, Д. Е. Каратеев, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain B. McInnes, Eduardo Mysler, Peter Nash, Karel Pavelká, Gyula Poór, Christophe Richez, Piet L. C. M. van Riel, Andrea Rubbert‐Roth, Kenneth G. Saag, José António Pereira da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Издательство: BMJ
Источник: Annals of the Rheumatic Diseases
Ключевые слова: Rheumatoid Arthritis Research and Therapies, Biosimilars and Bioanalytical Methods, Autoimmune and Inflammatory Disorders Research
Другие ссылки: Annals of the Rheumatic Diseases (PDF)
Annals of the Rheumatic Diseases (HTML)
HAL (Le Centre pour la Communication Scientifique Directe) (HTML)
HAL (Le Centre pour la Communication Scientifique Directe) (HTML)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (HTML)
Radboud Repository (Radboud University) (PDF)
Radboud Repository (Radboud University) (HTML)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (HTML)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (HTML)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (HTML)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (HTML)
Notes and Queries (PDF)
Notes and Queries (HTML)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (HTML)
Enlighten: Publications (The University of Glasgow) (HTML)
University of Birmingham Research Portal (University of Birmingham) (HTML)
University of Birmingham Research Portal (University of Birmingham) (PDF)
University of Birmingham Research Portal (University of Birmingham) (HTML)
Research Explorer (The University of Manchester) (HTML)
Research Explorer (The University of Manchester) (HTML)
PubMed (HTML)